Repertoire Immune Medicines

What Repertoire Immune Medicines does

Repertoire Immune Medicines is a clinical-stage biotechnology company developing programmable T cell-targeted immune medicines for patients with cancer and autoimmune diseases. The company operates two proprietary technology platforms: DECODE, a discovery platform that comprehensively maps the immune synapse to identify TCR-epitope pairs using proprietary components including MEDi (Mammalian Epitope Display), Multimer Technology, MCR (Massively Parallel Cellular Receptor Deorphanization, up to 10 million peptide-MHC combinations), and the NEPTUNE machine learning layer; and DEPLOY, a product platform comprising PRIME (dendritic cell priming), TETHER (immunomodulators) and STREAM (T cell biomanufacturing). Its pipeline includes the lead TCR bispecific RPTR-1-201 (Phase 1/2 with FDA Fast Track Designation in TNBC), additional TCR bispecifics (RPTR-1-301, RPTR-1-004, RPTR-1-005), the autologous PRIME IL-15 (RPTR-147) and PRIME IL-12 (RPTR-168) T cell therapies, mRNA cancer vaccines (RPTR-2-001 for NSCLC), and mRNA tolerizing vaccines (RPTR-3-001 for Type 1 Diabetes).

Repertoire generates revenue through a licensing and partnership model, executing multi-year strategic collaborations with major pharmaceutical companies in which it receives upfront payments, development and commercial milestone payments, and tiered royalties on net sales. The company leads discovery through candidate nomination while partners handle later-stage clinical development, manufacturing, regulatory affairs and commercialization. Active flagship collaborations include Eli Lilly (up to $1.93B, autoimmune tolerizing therapies), Bristol Myers Squibb (up to $1.87B, mRNA tolerising vaccines), Genentech (autoimmune T cell therapies), and Pfizer (prostate cancer TCR bispecifics). The company has raised over $350M in cumulative funding, is backed by Flagship Pioneering as founding investor, and operates from Cambridge, Massachusetts with a Zurich, Switzerland site.

Name

Repertoire Immune Medicines

Legal name

Repertoire Immune Medicines, Inc.

Website

https://repertoire.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

101–250 employees

Short description

Repertoire Immune Medicines is a clinical-stage biotechnology company that uses its proprietary DECODE platform to map the immune synapse and develop programmable T cell-targeted immune medicines — including TCR bispecifics, mRNA cancer vaccines, and mRNA tolerizing vaccines — for cancer and autoimmune disease patients, monetizing through upfront and milestone-based licensing deals with major pharmaceutical partners.

Ownership category

akta.pro rank

Product category

Biotechnology - Immune Medicines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB)

akta.pro secondary industries

CAR-T & TCR-T Therapies (HLAAABAC), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• TCR bispecific therapies
• MRNA tolerizing vaccines
• Immune synapse decoding
• T cell receptor discovery
• Programmable immune medicines

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Licensing and Partnership Deals: Repertoire generates revenue through strategic collaborations with large pharmaceutical companies. The company receives upfront payments, milestone payments tied to development and commercial achievements, and tiered royalties on net sales. Examples include deals with Eli Lilly (up to $1.93B), Bristol Myers Squibb (up to $1.87B), and Genentech.
2. Research Collaborations: The company enters into research collaborations with academic institutions and healthcare organizations for discovery and development programs, providing technology access and research services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Repertoire Immune Medicines is a clinical-stage biotechnology company that discovers and develops programmable T cell-targeted immune medicines for cancer and autoimmune diseases. Its proprietary DECODE platform maps the immune synapse to identify TCR-epitope pairs, which are translated into TCR bispecifics, mRNA cancer vaccines, and mRNA tolerizing vaccines, while its DEPLOY platform enables PRIME cytokine-tethered autologous T cell therapies and scalable biomanufacturing. The company monetizes its pipeline primarily through pharmaceutical partnership and licensing deals with large pharma, retaining discovery and early development responsibilities.

Product overview

Repertoire Immune Medicines is a clinical-stage biotechnology company with two core platforms: DECODE (discovery platform) and DEPLOY (product platform). The DECODE platform maps the immune synapse to identify TCR-epitope pairs and translate insights into T cell-targeted immune medicines. The DEPLOY platform enables production of autologous T cell therapies. The company's product portfolio includes: TCR bispecific immune medicines (RPTR-1-201 in Phase 1/2, RPTR-1-301 in IND enabling, RPTR-1-004 and RPTR-1-005 in earlier stages) for solid tumors; mRNA cancer vaccines (RPTR-2-001 for NSCLC); and mRNA tolerizing vaccines for autoimmune diseases (RPTR-3-001 for Type 1 Diabetes, plus programs with Lilly, Genentech, and BMS). The company also developed PRIME cytokine-tethered T cell therapies (PRIME IL-15 and PRIME IL-12) as investigational treatments. Key platform components include MEDi (epitope display), Multimer Technology (T cell screening), MCR (TCR deorphanizing), and NEPTUNE (machine learning).

Differentiator

Problem solved

Functional benefit

Products and services

• RPTR-1-201 (TCR bispecific immune medicine) Investigational TCR bispecific immune medicine comprising an engineered TCR that binds a tumor-selective epitope and an anti-CD3 moiety that engages and redirects T cells to kill tumor cells; in Phase 1/2 development for multiple advanced solid tumors and granted FDA Fast Track Designation in triple-negative breast cancer.
• PRIME IL-15 (RPTR-147) Investigational autologous, non-genetically modified multi-clonal T cell product loaded with IL-15Fc nanogel designed to release IL-15 locally and in a sustained manner for patients with advanced metastatic solid tumors.
• PRIME IL-12 (RPTR-168) Investigational autologous multi-targeted T cell therapeutic candidate using proprietary TETHER technology to deliver interleukin-12 (IL-12) to HPV-16-positive solid tumors.
• mRNA Tolerizing Vaccines Investigational off-the-shelf mRNA tolerizing vaccines comprised of disease-relevant, tissue-specific epitopes discovered using the DECODE platform, encoded by mRNA and encapsulated in proprietary lipid nanoparticles with an mRNA-encoded immune modulator, designed to restore immune homeostasis without generalized immune suppression in autoimmune diseases.
• mRNA Cancer Vaccines Investigational off-the-shelf mRNA cancer vaccines comprising shared and highly immunogenic tumor-specific epitopes encoded by mRNA and encapsulated in lipid nanoparticles for systemic delivery to activate cytotoxic T cells against solid tumors such as NSCLC.
• DECODE Discovery Platform Repertoire's proprietary discovery platform that comprehensively maps the immune synapse between T cell receptors and their cognate antigenic epitopes, enabling the identification of TCR-epitope pairs for the development of programmable immune medicines for cancer and autoimmune disease.
• DEPLOY Product Platform Repertoire's product-based platform that combines PRIME dendritic cell priming technology, TETHER immunomodulator platform for T cell-directed immune activation, and STREAM autologous high-yielding scalable T cell biomanufacturing.

Quantifiable outcome

• 10 of 17 patients with advanced metastatic disease showed stable disease in PRIME IL-15 trial, with 4 stable for more than 6 months
• +3 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Nine partnerships are on record, tiered flagship, major, supporting and core.

• Eli Lilly and CompanyflagshipStrategic or Co-development Partner · 29 January 2026Strategic collaboration worth up to $1.93 billion to develop tolerizing therapies for multiple autoimmune diseases. Repertoire receives $85 million upfront with additional payments of up to $1.84 billion tied to development and commercial milestones, plus tiered royalties on net sales. Repertoire leads activities until development candidate nomination using its DECODE platform while Lilly handles clinical development, manufacturing, regulatory affairs, and commercialization.
• PfizermajorStrategic or Co-development Partner · 22 December 2025Strategic partnership under Flagship's collaboration with Pfizer to identify T cell-targeted immune medicines for prostate cancer. Flagship Pioneering's unit Repertoire and Pioneering Medicines are collaborating with Pfizer to develop TCR bispecifics for metastatic prostate cancer. This marks the eighth program under Flagship's strategic partnership with Pfizer since July 2023.
• GenentechmajorStrategic or Co-development Partner · 23 April 2025Collaboration and license agreement for the development of T cell-targeted therapies for an autoimmune disease. Repertoire will utilize its DECODE platform for epitope discovery while Genentech handles further development and commercialization.
• Bristol Myers SquibbflagshipStrategic or Co-development Partner · 29 April 2024Multi-year strategic collaboration worth up to $1.87 billion to develop mRNA-based tolerising vaccines for autoimmune diseases. Bristol Myers Squibb committed up to $1.87 billion to leverage Repertoire's DECODE platform for tolerizing vaccine development.
• UMass Chan Medical SchoolsupportingStrategic or Co-development Partner · 17 February 2022Sponsored research agreement to identify specific T cell receptors and antigens causing onset and progression of vitiligo. The research collaboration utilizes Repertoire's DECODE platform to identify the immunogenic drivers of vitiligo for development of antigen-specific therapeutic candidates. Led by Dr. John E. Harris, Chair and Professor of Dermatology.
• Yale UniversitysupportingStrategic or Co-development Partner · 29 April 2021Research collaboration focused on understanding cellular immunity in multiple sclerosis by determining what types of antigens are activating T cells in patients. Repertoire uses its DECODE platform to determine novel antigens that TCR sequences from Yale identify. Led by Dr. David A. Hafler.
• Dana-Farber Cancer InstitutesupportingStrategic or Co-development Partner · 11 February 2021Research collaboration to identify novel antigen targets within HPV+ head and neck cancers. Dana-Farber provides blood and tissue samples while Repertoire uses its DECODE platform to identify novel antigens and evaluate tumor antigen expression. Dana-Farber is also a clinical trial site for PRIME IL-15 study.
• COVID-19 High Performance Computing ConsortiumsupportingStrategic or Co-development Partner · 24 June 2020Repertoire received funding from the COVID-19 HPC Consortium to identify viral epitopes with highest likelihood of inducing long-term immunity when delivered through vaccines. The project leverages cloud computing resources from AWS to simulate complex immunological interactions across patient populations.
• JDRF T1D FundcoreStrategic or Co-development Partner · 25 March 2020Investment from JDRF T1D Fund to advance Repertoire's platform for innovative cures to treat Type 1 Diabetes. The venture philanthropy fund focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes invested to enable Repertoire to utilize its core platforms to discover new antigens and T cell receptors for T1D treatments.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Immunocore: Immunocore is a clinical-stage biotech developing TCR bispecifics (ImmTAC platform), most notably tebentafusp, the first TCR therapeutic approved for solid tumors. It is the most direct competitor to Repertoire's RPTR-1-201 TCR bispecific program and shares the same core modality and target discovery approach.
• Adaptimmune: Adaptimmune develops engineered TCR-T cell therapies for solid tumors, with afami-cel approved for synovial sarcoma. It competes directly with Repertoire's PRIME autologous T cell and TCR bispecific programs in the same solid tumor indications.
• Cue Biopharma: Cue Biopharma develops TCR-based biologic drugs (Immuno-STAT platform) designed to selectively modulate T cells against cancer and autoimmune disease. It uses a similar TCR-directed approach to Repertoire's PRIME and TETHER platforms, targeting the immune synapse.
• Adaptive Biotechnologies: Adaptive Biotechnologies maps T cell receptors at scale through its immune profiling platform and develops TCR-based therapeutics, including partnerships with Genentech. It overlaps with Repertoire's DECODE platform in immune repertoire sequencing and TCR discovery.
• Neogene Therapeutics: Neogene Therapeutics develops personalized TCR-T cell therapies for solid tumors using neoantigen-targeting TCRs. Acquired by AstraZeneca in 2023, it represents an institutional competitor in personalized TCR therapy and overlaps with Repertoire's PRIME/TCR discovery approach.

Broad incumbents

• BioNTech: BioNTech is a leading mRNA therapeutics company with extensive cancer vaccine programs (BNT122 and others) and immunology partnerships with BMS and Genentech. It overlaps with Repertoire's mRNA cancer vaccine and mRNA tolerizing vaccine approach but operates at vastly greater scale and pipeline breadth.
• Moderna: Moderna is a leading mRNA platform company with oncology (mRNA-4157/V940 with Merck) and infectious disease vaccine programs. While not directly competing in TCR therapeutics, it competes with Repertoire's mRNA vaccine approach in cancer and autoimmune disease.
• bluebird bio: bluebird bio is a gene and cell therapy company with approved products in sickle cell disease and beta thalassemia. It shares an autologous cell therapy manufacturing paradigm with Repertoire's PRIME platform and competes for the same clinical development talent and CDMO capacity.

Emerging players

• Allogene Therapeutics: Allogene is a clinical-stage company developing allogeneic CAR-T cell therapies for hematologic and solid tumors. It competes with Repertoire's autologous PRIME T cell platform as an alternative cell therapy modality with potentially superior scalability and cost-of-goods.
• Marengo Therapeutics: Marengo Therapeutics develops TCR-based immunotherapies using a selective TCR agonism platform, including partnerships with AstraZeneca. It is a smaller emerging player targeting the T cell receptor pathway similar to Repertoire's PRIME and TETHER programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/RepertoireIM
• LinkedInlinkedin.com/company/repertoire-immune-medicines

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds5 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Repertoire Immune Medicines